MediPharm Labs Corp. (MEDIF)
| Market Cap | 22.81M |
| Revenue (ttm) | 32.59M |
| Net Income (ttm) | -6.35M |
| Shares Out | n/a |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150 |
| Average Volume | 137,237 |
| Open | 0.0538 |
| Previous Close | 0.0550 |
| Day's Range | 0.0538 - 0.0600 |
| 52-Week Range | 0.0379 - 0.0850 |
| Beta | 0.32 |
| RSI | 53.34 |
| Earnings Date | Aug 14, 2025 |
About MediPharm Labs
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, develops, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll canna... [Read more]
Full Company ProfileFinancial Performance
In 2024, MediPharm Labs's revenue was 41.96 million, an increase of 26.92% compared to the previous year's 33.06 million. Losses were -10.69 million, -18.26% less than in 2023.
Financial numbers in CAD Financial StatementsNews
MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis
Q2 Revenue of $11.8 Million, an Increase of 14% over Q2 2024 50% Growth in Revenue for International Medical Cannabis International Medical sales now 57% of Total Revenue Cash Balance of $10.4 Million...
MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States
MediPharm Labs holds unique US Food and Drug Administration (FDA) site registration in relation to the manufacturing and release of pharmaceutical cannabis products. MediPharm is the only US FDA Aud...
MediPharm Labs Sets Date to Report Second Quarter 2025 Financial Results
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precisi...
MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler
TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specializing in precisi...
MediPharm Announces Voting Results from the 2025 Annual and Special Meeting of Shareholders
TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoi...
MediPharm Cautions Shareholders To Await Final Results of Annual and Special Meeting
TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoi...
Apollo Capital Wins Proxy Contest at MediPharm Labs
MediPharm Labs' Board's Material and Unprecedented Breaches of Securities Laws Are Part of Their Undoing
Leading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees
TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoi...
MediPharm Reminds Shareholders to Vote in Advance of June 13 Deadline
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm,” the “Company,” “we” or “us”), a pharmaceutical company specialized in precision-base...
MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoi...
Apollo Capital Releases Investor Presentation Highlighting Plan to Make MediPharm Labs the World's Leading International Medical Cannabis Company
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Apollo Technology Capital Corporation (“Apollo Capital”), which together with its affiliates and associates collectively is one of the largest shareholders o...
MediPharm Labs' Founder-CEO Pat McCutcheon Throws his Support behind Apollo Capital as Dissident
McCutcheon Agrees with Apollo that Urgent Change is Needed, including Complete Turnover at the Board Level after Years of Value-Destruction
MediPharm Labs' Board Continues Value Destruction for Shareholders with Sale of Hope Facility
Complete Incompetence at the Board Level Results in Fire Sale of Treasured MediPharm Asset, the Hope Facility, to a Competitor
MediPharm Labs Closes $4.5 Million Sale of Hope, BC Facility and Announces Plans to Expand EU GMP Cultivation Capacity at Napanee Facility
TORONTO, June 05, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm"), a pharmaceutical company specialized in precision-based cannabinoids, announced the...
Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo's Arguments and Director Slate
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoi...
MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital
Demands Management's Board Nominees John Medland and Emily Jameson Withdraw Immediately or Face Public Complicity in Ongoing Alleged Systemic Violations of Securities Laws
MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder
MediPharm Labs responds to allegations from dissident shareholder Apollo, intentionally or recklessly fabricated as part of its campaign of misinformation.
Alleged Securities Fraud at MediPharm Labs Says Apollo Capital
Multiple Highly Credible Sources Reveal Disturbing Evidence of Alleged Systemic Violations of Securities Laws at MediPharm Labs; Immediate Regulatory Action Demanded Apollo Capital's Six Director Nomi...
MediPharm Labs Board Issues Letter to Shareholders in Response to Inadequate Dissident Plan
TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today issued a Letter t...
MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement
TORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision...
MediPharm Labs Cautions Shareholders about Dissident Nominees' Governance Failures at Check-Cap Ltd.
TORONTO, May 23, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (“MediPharm”, the “Company”, or “we”), a pharmaceutical company specialized in precision-based cannabinoids, today provided i...
Apollo Capital Comments on MediPharm Labs' Failure to Respond to Reasonable Offer to Ensure Fair, Lawful and Transparent 2025 Annual Meeting
MediPharm Labs Board Continues to Obstruct the Appointment and Oversight of an Independent Chair Failure to Appoint an Independent Chair to Oversee the Election of Directors at the Annual Meeting Prev...
MediPharm Achieves Key Milestone Toward $4.5 Million Cash Sale of Hope Facility, On Track to Close in June
TORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce ...
Apollo Capital Issues a With Prejudice Offer to MediPharm Labs and Its Board of Directors to Ensure Shareholder Rights Are Protected at the 2025 Annual Meeting
Believes the Board Continues to Take Oppressive Actions Which Fundamentally Disregard the Rights and Interests of Shareholders
MediPharm Labs Alerts Shareholders to Allegations Made Against Regan McGee in Multiple Litigation Filings
TORONTO, May 21, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today alerted its share...